Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Hikma Pharmaceuticals Plc    HIK   GB00B0LCW083

Delayed Quote. Delayed  - 06/24 05:35:23 pm
2271 GBp   +1.38%
06/14 HIKMA PHARMACEU : receives FDA approval for Letrozole Tablets
06/07 HIKMA PHARMACEU : Egypt launches Hikma Specialized division to bring..
06/06 HIKMA PHARMACEU : receives FDA approval for Ketamine Hydrochloride I..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Hikma Pharmaceuticals : receives FDA approval for Letrozole Tablets

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/14/2016 | 04:39pm CEST

Release date- 13062016 - London- Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, announces that its wholly-owned subsidiary West-Ward Pharmaceuticals, has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Letrozole Tablets 2.5mg.

Letrozole is a chemotherapy drug indicated for the treatment of breast cancer. According to IMS Health, total U.S. sales of Letrozole Tablets 2.5 mg were approximately $21 million for the 12 months ending April 2016.

Said Darwazah, Chairman and CEO of Hikma said, 'We are very pleased to have our first FDA approval from Hikma's dedicated oncology plant in Sahab, Jordan. We continue to leverage our strong global R&D teams and high-quality operational capabilities, to enhance our growing portfolio of more differentiated products.'

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: 'Injectables', 'Branded' and 'Generics', based principally in the United States, the Middle East and North Africa (MENA) and Europe. In 2015, Hikma achieved revenue of $1,440 million and profit attributable to shareholders of $252 million.

Enquiries

Hikma Pharmaceuticals PLC

Susan Ringdal, VP Corporate Strategy and Investor Relations +44 (0)20 7399 2760/

+44 7776 477050

Lucinda Baker, Deputy Director of Investor Relations +44 (0)20 7399 2765/

+44 7818 060211

Zeena Murad, Investor Relations Manager +44 (0)20 7399 2768/

+44 7771 665277

FTI Consulting

Ben Atwell / Matthew Cole +44 (0)20 3727 1000

(c) 2016 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on HIKMA PHARMACEUTICALS PLC
06/14 HIKMA PHARMACEUTICALS : receives FDA approval for Letrozole Tablets
06/07 HIKMA PHARMACEUTICALS : Egypt launches Hikma Specialized division to bring advan..
06/06 HIKMA PHARMACEUTICALS : receives FDA approval for Ketamine Hydrochloride Injecti..
06/05 ARAB FINANCIAL INVESTMENT : Hikma to bring advanced medicines to patients in nee..
06/01 Hikma Pharmaceuticals Rejoins FTSE 100, Smurfit Kappa Joins FTSE 250
06/01 HIKMA PHARMACEUTICALS : announces FDA approval and launch of Fluticasone 50 MCG ..
05/25 HIKMA PHARMACEUTICALS : Michael Raya, CEO of West-Ward Pharmaceuticals, Hikma's ..
05/24 DIRECTOR DEALINGS : Hikma Pharmaceuticals CFO Sells 20,000 Shares
05/20 HIKMA PHARMACEUTICALS : wins Mitigare / Colchicine patent infringement case
05/19 HIKMA PHARMACEUTICALS : Says US Court Dismisses Claims Made By Takeda
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials